Updated:
Iridescent Capital Management
IRIDESCENT CAPITAL MANAGEMENT is a state-registered investment adviser. The firm manages approximately $296,703 in assets. It has 1 employee and 1 investment...
Iridescent Capital Management
IRIDESCENT CAPITAL MANAGEMENT is a state-registered investment adviser. The firm manages approximately $296,703 in assets. It has 1 employee and 1 investment adviser.
General information
Firm type
RIA
Year founded
2009
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
Los Angeles, CA, United States
Principals
Thomas Tull
Founder & Chairman
Sector focus
Frequently asked questions
Who makes investment decisions at Iridescent Capital Management?
Thomas Tull, the founder and sole principal, makes all investment decisions. Tull built his investment approach during his tenure as CEO of Legendary Entertainment, where he used quantitative models to forecast box-office performance. No non-family CIO or investment committee has been publicly identified.
Where does Thomas Tull's wealth come from?
Tull's wealth originates from the 2016 sale of Legendary Entertainment to China's Wanda Group for $3.5 billion (per Bloomberg, 2016). Before founding Legendary, Tull operated a private equity firm and previously ran a chain of laundromats. The Wanda transaction provided the capital base from which Iridescent Capital Management deploys today.
What is Iridescent's relationship to the Pittsburgh Steelers?
Thomas Tull was formerly a minority owner of the Pittsburgh Steelers. He reduced his stake to comply with NFL cross-ownership rules after acquiring additional sports-related assets through Iridescent. The precise current ownership percentage is not publicly disclosed.
What does Iridescent invest in beyond technology and media?
The office maintains three core verticals: media and entertainment technology, enterprise software with defense and national-security crossover, and professional sports ownership. Iridescent has also backed life sciences companies, notably Excision BioTherapeutics, where the connection to Tull's thesis lies in applied machine learning and data-driven risk modeling rather than traditional biotech venture capital.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: